Credit: Getty Images
Schizophrenia Bulletin Open confirms.
The study analyzed clinical trial reports to determine short- and long-term effects of brexpiprazole across schizophrenia symptoms based on the Positive and Negative Syndrome Scale (PANSS) and five subscales.
To study short-term effects, the researchers used data from 3 randomized, double-blind, placebo-controlled brexpiprazole studies in patients with acute schizophrenia. Long-term maintenance effects were studied using the 52-week Equator clinical trial. Two additional studies were also used to measure long-term effects.
Continue Reading
In the short-term studies, patients in the brexpiprazole group were associated with greater improvement in each subscale score from baseline to week 6 compared with the control group participants. The patients using the antipsychotic were also associated with greater improvement in 25 of 30 PANSS scale symptoms at week 6 compared with the control group participants. Improvement was a
New Oral Medication Offers Established Antipsychotic Efficacy of Olanzapine With Less Weight Gain Commercial Launch Planned for Fourth Quarter 2021 Company to Host Investor
/PRNewswire/ Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved LYBALVI™ (olanzapine and samidorphan).